JMP Securities analyst Patrick Walravens maintained a Buy rating on Vertex (VERX – Research Report) today and set a price target of $61.00. The company’s shares closed yesterday at $36.45.

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the company on March 13 at a price of $510 per share.